Fig. 5

Effect of SFRP1 protein in VCaP xenograft. SFRP1 treatment was performed every week for 10 weeks. SFRP1 was subcutaneously applied around the tumor (50 µl at 0.01 nM) (a). Representative photography for every xenograft in each treatment. In IHC, Ki67 as proliferative marker were showed at ×10 and ×60 magnification. ki67 IHC at 10X was quantify as signal of positive cells*area, **p ≤ 0.008 (b). Human PSA was quantified by ELISA (c). Immunohistochemistry of VCaP xenografts, tissues were collected after euthanasia in formalin, then embedded in paraffin, and IHC for ERG was performed (d). TMPRSS2-ERG expression (mRNA) and ERG (protein) in VCaP xenografts. Tissue was processed for RNA isolation and protein extraction and RT-qPCR and W.B. were performed, *p ≤ 0.03 (mRNA) and *p ≤ 0.01 (protein) (e–g)